SEC 13F Intelligence

Bowen Hanes & Co Inc / VRTX

Bowen Hanes & Co Inc’s Vertex Pharmaceuticals Inc Position

Does Bowen Hanes & Co Inc own Vertex Pharmaceuticals Inc (VRTX)? Yes135.4K shares worth $60M (+1.47% of its 13F portfolio) as of Q1 2026, up from 133.5K shares the prior filed quarter.

Position Value
$60M
Q1 2026
Shares
135.4K
% of Portfolio
+1.47%
Quarters Held
30
currently held

Position History VRTX

Reported value by quarter
Q4 ’18: $25MQ4 ’18Q1 ’19: $28MQ2 ’19: $28MQ3 ’19: $25MQ4 ’19: $30MQ4 ’19Q1 ’20: $32MQ2 ’20: $38MQ3 ’20: $36MQ4 ’20: $31MQ4 ’20Q1 ’21: $56MQ2 ’21: $30MQ3 ’21: $32MQ4 ’21: $43MQ4 ’21Q1 ’22: $50MQ2 ’22: $54MQ3 ’22: $52MQ4 ’22: $51MQ4 ’22Q1 ’23: $55MQ2 ’23: $61MQ3 ’23: $61MQ4 ’23: $71MQ4 ’23Q1 ’24: $74,311Q2 ’24: $84MQ3 ’24: $83MQ4 ’24: $73MQ4 ’24Q1 ’25: $87MQ2 ’25: $80MQ3 ’25: $49MQ4 ’25: $60,525Q4 ’25Q1 ’26: $60Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026135.4K$60M+1.47%
Q4 2025133.5K$60,525+1.52%
Q3 2025124.4K$49M+1.22%
Q2 2025180.8K$80M+2.03%
Q1 2025178.9K$87M+2.41%
Q4 2024180.6K$73M+1.95%
Q3 2024178.9K$83M+2.18%
Q2 2024179.5K$84M+2.33%
Q1 2024177.8K$74,311+2.12%
Q4 2023173.8K$71M+2.13%
Q3 2023175.4K$61M+2.05%
Q2 2023173.3K$61M+1.95%
Q1 2023174.9K$55M+1.89%
Q4 2022175.2K$51M+1.79%
Q3 2022181.0K$52M+2.03%
Q2 2022191.5K$54M+1.96%
Q1 2022192.6K$50M+1.50%
Q4 2021194.1K$43M+1.20%
Q3 2021178.6K$32M+1.00%
Q2 2021150.0K$30M+0.92%
Q1 2021262.0K$56M+0.92%
Q4 2020131.0K$31M+1.03%
Q3 2020131.0K$36M+1.34%
Q2 2020131.0K$38M+1.60%
Q1 2020135.0K$32M+1.61%
Q4 2019135.0K$30M+1.22%
Q3 2019150.0K$25M+1.08%
Q2 2019150.0K$28M+1.18%
Q1 2019150.0K$28M+1.22%
Q4 2018150.0K$25M+1.25%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Bowen Hanes & Co Inc’s full portfolio or all institutional holders of VRTX.